Venezuela

There is no evidence of a national population-wide dementia screening program in Venezuela, and in low-resource clinical settings the most practical cognitive tools remain brief, low-cost instruments such as the Mini-Mental State Examination (MMSE) and the Clock Drawing Test (CDT). Evidence from a Venezuelan neuropsychology service sample from Caracas suggests that MMSE and CDT, used separately or combined, have only moderate sensitivity for distinguishing people living with mild Alzheimer’s disease from cognitive unimpaired once age and years of education are taken into account, but those tests do not perform well for differential diagnosis across other common clinical presentations such as mild cognitive impairment, depression, or subjective cognitive complaints not confirmed on fuller assessment. Importantly, test performance is strongly shaped by education and age (with lower scores among older adults and those with fewer years of schooling), meaning that unadjusted cut-offs can misclassify people in a highly unequal educational context. In practice, this supports a “screen-and-triage” model in which MMSE and CDT can help flag likely dementia, especially for mild Alzheimer’s disease, yet clinicians often need contextual interpretation, collateral history, functional assessment, and, when possible, fuller neuropsychological evaluation to separate dementia from depression, benign forgetfulness, or other causes of cognitive complaints.

Neuroimaging (computed tomography (CT) and magnetic resonance imaging (MRI) is concentrated primarily in major urban centers and is used mainly to exclude secondary causes of cognitive decline and support differential diagnosis when accessible. However, actual availability and accessibility reflect a deep divide between public and private sectors. While CT and basic MRI scans are present in the private sector, high costs make them prohibitive for the majority of the population. Public healthcare facilities face persistent equipment downtime, maintenance deficits, and severe resource constraints, leaving vulnerable patients facing extensive waitlists or a total lack of imaging accessibility. Advanced dementia imaging techniques such as FDG-PET and amyloid PET are not routinely available and are generally restricted to research settings or require referral abroad.

There is no evidence that routine genetic testing for Alzheimer’s disease is a part of the standard diagnostic pipeline within the public health network of Venezuela. Testing for risk-susceptibility genes, such as the Apolipoprotein E epsilon 4 (APOE-ε4) allele, or definitive causative mutations in familial Alzheimer’s (such as PSEN1, PSEN2, and APP), is restricted to academic registries and longitudinal cohort studies.

There is no public evidence of standardised Alzheimer’s disease biomarker pathways, such as cerebrospinal fluid (CSF) Aβ/tau panels or blood-based biomarkers, embedded in routine care in Venezuela. Given the documented constraints on specialty care access and system capacity, biomarker use, if present, is likely sporadic, centre-dependent, and privately financed, rather than incorporated into a national diagnostic algorithm.

Venezuela is not publicly profiled as having a national memory-clinic network or a dedicated dementia service tier. Instead, dementia care is largely embedded within general neurology and psychiatry services, primarily located in major urban centers, alongside ad hoc referrals to psychology or neuropsychology where available. Historically, clinical literature from Venezuela and comparable Latin American contexts shows that dementia services have been shaped more by overall health-system capacity and workforce availability than by purpose-built dementia infrastructure. This structural pattern has been significantly intensified under current crisis conditions, where hospital functionality, staffing levels, and diagnostic capacity fluctuate over time and geography. As a result, continuity of dementia care depends heavily on where people live, which services are operational at a given moment, and whether families can navigate multiple entry points. Civil society organizations in urban areas play an important bridging role, helping families identify available clinicians, interpret diagnoses, and cope with fragmented service provision, but these supports are unevenly distributed and largely inaccessible outside major cities.

Dementia care in Venezuela represents a substantial and often catastrophic financial load for households. Because financing is heavily household-based in practice, costs accumulate across repeated consultations, private diagnostic tests, medication purchases, transportation, and adaptive care needs. Even when some services are theoretically available in the public sector, indirect costs and system gaps frequently push families into private spending to maintain continuity of care. The most significant hidden cost is unpaid caregiving time, which often falls on family members, typically women, who may reduce or abandon paid employment to provide full-time care. In the context of economic instability and limited social protection, dementia care can therefore trigger long-term household impoverishment, reinforcing inequalities in who can sustain ongoing treatment and support.

Carer support in Venezuela is predominantly non-governmental organisation (NGO)- and community-driven, rather than embedded in formal state programs. The Fundación Alzheimer de Venezuela functions as a visible hub for information, counselling, and guidance, particularly in the Caracas-Baruta area, and often serves as a practical first point of contact for families seeking help. Its activities include education, awareness-raising, and signposting rather than formal service provision, reflecting both necessity and resource constraints. There is no clear evidence of national carer benefit schemes or dementia-specific social entitlements. Broader reporting on health and social-service limitations suggests that carers rely primarily on informal family networks, community solidarity, and NGO support rather than structured state assistance. This places sustained caregiving at risk, particularly for lower-income households and those outside major urban centers, and further underscores the central role of civil society in Venezuela’s dementia ecosystem.

There is no clear public evidence of a dedicated, operational national dementia plan in Venezuela with defined objectives, financing, timelines, or monitoring mechanisms. Regional health policy literature notes that Venezuela has at times been grouped among Latin American countries working toward dementia strategies, but this framing reflects aspirational or conceptual engagement rather than formal adoption and implementation. In practical terms, dementia appears to be addressed indirectly, subsumed within broader discussions on mental health, ageing, disability, and chronic disease, rather than treated as a standalone policy priority with its own governance structure. As a result, dementia policy lacks the institutional anchors typically associated with national plans, such as standardized care pathways, service benchmarks, workforce planning targets, or dedicated budget lines. The absence of these elements means that policy intent does not reliably translate into service delivery, and dementia care remains contingent on general system capacity rather than protected through disease-specific planning.

Innovation in Venezuela’s dementia space is predominantly adaptive rather than technological. Rather than biomarker platforms, precision diagnostics, or advanced neuroimaging research, innovation focuses on service adaptation and workforce training. This aligns with PAHO-supported approaches that emphasize integrating dementia recognition into general clinical and mental-health training, particularly for frontline providers working in low-resource and unstable settings. Such models prioritize early identification, basic cognitive assessment, referral awareness, and caregiver guidance, aiming to preserve clinical capacity under constraint. While this approach does not expand access to advanced diagnostics, it represents a pragmatic effort to maintain minimum diagnostic competence and continuity of care in a severely resource-limited environment.

In 2009, 10/66 Dementia Research Group, a global research consortium coordinated through Alzheimer’s Disease International (ADI) and led academically by King’s College London’s Institute of Psychiatry, Psychology & Neuroscience. In Venezuela, this work was anchored in Central University of Venezuela and its affiliated academic hospital and neuropsychology units, which served as key national centres for data collection, clinical evaluation, and carer-focused interventions. Through standardized, cross-cultural instruments applied across multiple countries, the network demonstrated that dementia prevalence in Venezuela and other low- and middle-income settings had been significantly underestimated and that dementia is a leading driver of disability and dependency among older adults. The research also highlighted the interaction between dementia and poorly controlled chronic conditions such as diabetes and hypertension, reflecting broader gaps in access to basic medical care. Importantly, the work extended beyond measurement: university- and hospital-based teams piloted structured caregiver training interventions, delivered through clinical and community settings, which showed tangible improvements in household functioning and carer wellbeing. Findings from these centers have fed into regional policy work with the PAHO, influencing geriatric and ageing strategies across Latin America and contributing to global WHO and World Alzheimer Report.